Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Wave Life Sciences, Inc.WVE · Entity 4976 | Director | October 05, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Wave Life Sciences, Inc.
Report date October 05, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,779 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 10,700 · Balance 30,779 F1: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.75 · Expires 2036-10-05 | Direct | 64,000 |
Reported balance
After 2026-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-05 · Grant · Acquired 64,000 · Balance 64,000 F2: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 9,606,408 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 9,606,408 F3: Includes an aggregate of (i) 6,107,593 shares of common stock held by SNBL USA, Ltd. ("SNBL USA") and (ii) 3,498,815 shares of common stock held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"). F4: Ken Takanashi, a director of the Issuer, is a director of SNBL USA and SNBL and Mr. Takanashi may be deemed to beneficially own the reported securities held by SNBL USA and SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL USA and SNBL, except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL USA or SNBL. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
F2: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
F3: Includes an aggregate of (i) 6,107,593 shares of common stock held by SNBL USA, Ltd. ("SNBL USA") and (ii) 3,498,815 shares of common stock held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL").
F4: Ken Takanashi, a director of the Issuer, is a director of SNBL USA and SNBL and Mr. Takanashi may be deemed to beneficially own the reported securities held by SNBL USA and SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL USA and SNBL, except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL USA or SNBL.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Satsuma Pharmaceuticals, Inc.
Report date June 06, 2023 · Filed June 08, 2023
Section 16 reporting ended · disclosed 2023-06-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectSee Footnote | 24,847,694 |
Reported balance
After 2023-06-06 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-06-06 · Purchase · Acquired 22,053,581 · Balance 24,847,694 F1: All of the shares were cancelled on June 8, 2023 pursuant to the terms of that certain Agreement and Plan of Merger, dated April 16, 2023, by and between the Issuer, Shin Nippon Biomedical Laboratories, Ltd., a Japanese corporation ("SNBL"), and SNBL23 Merger Sub, Inc. ("Merger Sub"), a Delaware corporation (the "Merger Agreement"). F2: Shares acquired by Merger Sub, upon acceptance of all shares validly tendered and not validly withdrawn pursuant to the tender offer by Merger Sub and SNBL, pursuant to the Merger Agreement, for any and all outstanding shares of Satsuma common stock pursuant to that certain Offer to Purchase, dated May 5, 2023. F3: Shares are held by SNBL and SNBL U.S.A., Ltd., a wholly owned subsidiary of SNBL. Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.99 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F4: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.60 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F4: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.46 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-08 · Disposition to issuer · Disposed 30,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F4: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the shares were cancelled on June 8, 2023 pursuant to the terms of that certain Agreement and Plan of Merger, dated April 16, 2023, by and between the Issuer, Shin Nippon Biomedical Laboratories, Ltd., a Japanese corporation ("SNBL"), and SNBL23 Merger Sub, Inc. ("Merger Sub"), a Delaware corporation (the "Merger Agreement").
F2: Shares acquired by Merger Sub, upon acceptance of all shares validly tendered and not validly withdrawn pursuant to the tender offer by Merger Sub and SNBL, pursuant to the Merger Agreement, for any and all outstanding shares of Satsuma common stock pursuant to that certain Offer to Purchase, dated May 5, 2023.
F3: Shares are held by SNBL and SNBL U.S.A., Ltd., a wholly owned subsidiary of SNBL. Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities.
F4: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.
F5: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 8, 2026 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantStock Option (right to buy) · Derivative | 64,000 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001193125-26-417235 · ownership.xml · derivative · entry 3 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2036-10-05 F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. Read SEC document |
| October 05, 2026 Filed Oct 8, 2026 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantCommon Stock | 10,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-417235 · ownership.xml · nonDerivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,779 F1 · shares: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. Read SEC document |
| August 11, 2026 Filed Aug 14, 2026 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleCommon Stock | 3,864 | $6.01 | $23,222.64 |
DisclosureSEC source: 0001193125-26-349961 · ownership.xml · nonDerivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,079 F1 · shares: On August 11, 2026, the reporting person sold 3,864 shares of common stock solely to cover taxes associated with the vesting of restricted stock units on August 11, 2026. These sales were made pursuant to a previously adopted 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for stock sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $6.01 to $6.03 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 23, 2026 Filed Mar 26, 2026 20:15 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | ConversionSeries A Preferred Shares · Derivative | 3,901,348 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-126276 · ownership.xml · derivative · entry 3 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Ordinary Shares · 3,901,348 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. ("SNBL USA") and Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026. F1 · date: The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. ("SNBL USA") and Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026. F1 · kind: The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. ("SNBL USA") and Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026. F2 · shares: Includes (i) 2,100,000 shares held by SNBL USA and (ii) 1,801,348 shares held by SNBL. F1 · derivative.exercise_date: The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. ("SNBL USA") and Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026. F1 · derivative.expiration_date: The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. ("SNBL USA") and Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026. F4 · ownership.nature: Ken Takanashi, a director of the Issuer, is a director of SNBL USA and SNBL and Mr. Takanashi may be deemed to beneficially own the reported securities held by SNBL USA and SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL USA and SNBL, except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL USA or SNBL. Read SEC document |
| March 23, 2026 Filed Mar 26, 2026 20:15 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | ConversionOrdinary Shares | 3,901,348 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-126276 · ownership.xml · nonDerivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 9,606,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. ("SNBL USA") and Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026. F1 · kind: The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. ("SNBL USA") and Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026. F2 · shares: Includes (i) 2,100,000 shares held by SNBL USA and (ii) 1,801,348 shares held by SNBL. F3 · balance_after: Includes an aggregate of (i) 6,107,593 shares held by SNBL USA and (ii) 3,498,815 shares held by SNBL. F4 · ownership.nature: Ken Takanashi, a director of the Issuer, is a director of SNBL USA and SNBL and Mr. Takanashi may be deemed to beneficially own the reported securities held by SNBL USA and SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL USA and SNBL, except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL USA or SNBL. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 76,200 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0000950170-25-108289 · ownership.xml · derivative · entry 2 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,200 Underlying: Ordinary Shares · 76,200 shares Expires 2030-08-11 F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2025 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 12,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-108289 · ownership.xml · nonDerivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,729,003 F1 · shares: The reporting person was granted this restricted share unit award (RSU) pursuant to the 2025 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026. Read SEC document |
| August 05, 2025 Filed Aug 8, 2025 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 4,872 | $8.75 | $42,630.00 |
DisclosureSEC source: 0000950170-25-105353 · ownership.xml · nonDerivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,716,303 F1 · shares: On August 5, 2025, the reporting person sold 4,872 ordinary shares solely to cover taxes associated with the vesting of restricted share units on August 5, 2025. These sales were made pursuant to a 10b5-1 Trading Plan. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 22:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 32,230 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0000950170-24-097283 · ownership.xml · derivative · entry 2 TAKANASHI KEN · CIK 0001657768 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,230 Underlying: Ordinary Shares · 32,230 shares Expires 2029-08-12 F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2024 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2025 annual general meeting or August 12, 2025. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 22:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 16,115 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-097283 · ownership.xml · nonDerivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,721,175 F1 · shares: The reporting person was granted this restricted share unit award (RSU) pursuant to the 2024 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2025 annual general meeting or August 12, 2025. Read SEC document |
| August 07, 2023 Filed Aug 10, 2023 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000899243-23-017915 · doc4.xml · derivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Ordinary Shares · 45,000 shares Expires 2028-08-07 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2024 annual general meeting or August 7, 2024. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:44 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0000899243-23-014896 · doc4.xml · derivative · entry 4 TAKANASHI KEN · CIK 0001657768 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:44 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0000899243-23-014896 · doc4.xml · derivative · entry 3 TAKANASHI KEN · CIK 0001657768 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:44 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.99 | $0.00 |
DisclosureSEC source: 0000899243-23-014896 · doc4.xml · derivative · entry 2 TAKANASHI KEN · CIK 0001657768 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 16:44 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | PurchaseCommon Stock, $0.0001 par value | 22,053,581 | $0.91 | $20,068,758.71 |
DisclosureSEC source: 0000899243-23-014896 · doc4.xml · nonDerivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 24,847,694 F1 · shares: All of the shares were cancelled on June 8, 2023 pursuant to the terms of that certain Agreement and Plan of Merger, dated April 16, 2023, by and between the Issuer, Shin Nippon Biomedical Laboratories, Ltd., a Japanese corporation ("SNBL"), and SNBL23 Merger Sub, Inc. ("Merger Sub"), a Delaware corporation (the "Merger Agreement"). F2 · shares: Shares acquired by Merger Sub, upon acceptance of all shares validly tendered and not validly withdrawn pursuant to the tender offer by Merger Sub and SNBL, pursuant to the Merger Agreement, for any and all outstanding shares of Satsuma common stock pursuant to that certain Offer to Purchase, dated May 5, 2023. F1 · balance_after: All of the shares were cancelled on June 8, 2023 pursuant to the terms of that certain Agreement and Plan of Merger, dated April 16, 2023, by and between the Issuer, Shin Nippon Biomedical Laboratories, Ltd., a Japanese corporation ("SNBL"), and SNBL23 Merger Sub, Inc. ("Merger Sub"), a Delaware corporation (the "Merger Agreement"). F3 · ownership.nature: Shares are held by SNBL and SNBL U.S.A., Ltd., a wholly owned subsidiary of SNBL. Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities. Read SEC document |
| August 15, 2022 Filed Aug 18, 2022 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000899243-22-029096 · doc4.xml · derivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2027-08-15 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2023 annual general meeting or August 15, 2023. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 17:36 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001567619-22-012473 · doc1.xml · derivative · entry 2 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-02 F2 · derivative.exercise_date: The option shall vest in full and become exercisable on the day immediately preceding the 2023 Annual Meeting. Read SEC document |
| June 03, 2022 Filed Dec 9, 2022 16:11 UTC Amendment | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001567619-22-021461 · doc1.xml · derivative · entry 2 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-02 F2 · derivative.exercise_date: The option shall vest in full and become exercisable on the day immediately preceding the 2023 Annual Meeting. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 22:11 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0000899243-21-033527 · doc4.xml · derivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Ordinary Shares · 42,000 shares Expires 2026-08-16 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 12.5% of the shares in equal quarterly installments over the two-year period following the grant date on August 16, 2021. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 18:05 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001567619-20-020722 · doc1.xml · derivative · entry 2 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-12-03 F2 · derivative.exercise_date: The option shall vest in full and become exercisable on the day immediately preceding the 2022 Annual Meeting. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:33 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023087 · doc4.xml · derivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 19:23 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $26.99 | $0.00 |
DisclosureSEC source: 0001567619-20-012248 · doc1.xml · derivative · entry 2 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-11 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the first Annual Meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board through the applicable vesting date. Read SEC document |
| September 17, 2019 Filed Sep 17, 2019 16:05 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | ConversionSeries B Preferred Stock · Derivative | 307,110 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-023732 · doc4.xml · derivative · entry 5 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See FN Disclosed balance after: 0 Underlying: Common Stock · 307,110 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering. F1 · shares: Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering. F2 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering. F2 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering. F2 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering. F1 · derivative.underlying_shares: Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering. F3 · ownership.nature: Shares are held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"). Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities. Read SEC document |
| September 17, 2019 Filed Sep 17, 2019 16:05 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | ConversionSeries A Preferred Stock · Derivative | 33,741 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-023732 · doc4.xml · derivative · entry 4 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See FN Disclosed balance after: 0 Underlying: Common Stock · 33,741 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering. F1 · shares: Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering. F2 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering. F2 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering. F2 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering. F1 · derivative.underlying_shares: Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering. F3 · ownership.nature: Shares are held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"). Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities. Read SEC document |
| September 17, 2019 Filed Sep 17, 2019 16:05 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | PurchaseCommon Stock, $0.0001 par value | 233,333 | $15.00 | $3,499,995.00 |
DisclosureSEC source: 0000899243-19-023732 · doc4.xml · nonDerivative · entry 3 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See FN Disclosed balance after: 1,561,719 F4 · kind: SNBL USA, Ltd., a subsidiary of SNBL, purchased an additional 233,333 shares of issuer's common stock in connection with the initial public offering at the offering price of $15.00 per share. F3 · ownership.nature: Shares are held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"). Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities. Read SEC document |
| September 17, 2019 Filed Sep 17, 2019 16:05 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | ConversionCommon Stock, $0.0001 par value | 307,110 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-023732 · doc4.xml · nonDerivative · entry 2 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See FN Disclosed balance after: 1,328,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering. F2 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering. F1 · balance_after: Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering. F3 · ownership.nature: Shares are held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"). Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities. Read SEC document |
| September 17, 2019 Filed Sep 17, 2019 16:05 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | ConversionCommon Stock, $0.0001 par value | 33,741 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-023732 · doc4.xml · nonDerivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See FN Disclosed balance after: 1,021,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering. F2 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering. F1 · balance_after: Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering. F3 · ownership.nature: Shares are held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"). Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 20:20 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $20.34 | $0.00 |
DisclosureSEC source: 0000899243-19-021963 · doc4.xml · derivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2024-08-15 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2020 annual general meeting or August 15, 2020. Read SEC document |
| August 13, 2018 Filed Aug 16, 2018 00:08 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $46.70 | $0.00 |
DisclosureSEC source: 0000899243-18-022512 · doc4.xml · derivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 9,000 shares Expires 2023-08-13 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 13, 2019. Read SEC document |
| August 10, 2017 Filed Aug 17, 2017 20:19 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $18.10 | $0.00 |
DisclosureSEC source: 0000899243-17-020602 · doc4.xml · derivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 9,000 shares Expires 2022-08-10 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 10, 2018. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 23:24 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0000899243-16-033374 · doc4.xml · derivative · entry 1 TAKANASHI KEN · CIK 0001657768 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 9,000 shares Expires 2021-11-10 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on November 10, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.